Preface

Excerpt

Prostate cancer is the most common non-skin malignancy in men with one in six men diagnosed within his lifetime. In 2013, there is an estimated 238,590 new cases of prostate cancer and nearly 30,000 deaths from this disease. As long as prostate cancer remains incurable, scientists and physicians will continue their fight to eradicate this highly morbid cancer. In the past decade, there has been significant innovation in prostate cancer research in the area of androgen receptor modulation, growth factor signaling pathways, tumor dormancy, immune regulation, and bone targeting pathways. These advancements have led to the exploration, development, and eventually, Food and Drug Administration (FDA) approval of several novel therapeutic agents for men with metastatic prostate cancer. Fortunately, new data generated in the laboratory are challenging the current clinical therapeutic paradigm, moving us closer to developing more effective treatment. Now, more than ever, it is essential to sustain constant translational dialogue between scientists and physicians. With new FDA-approved therapeutic options still in single digits, it is critical that we continue to advance in all areas of research including tumor metastasis, dormancy, and mechanisms of resistance. …